



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION APPOINTS PROF STUART CROZIER AS CHIEF SCIENTIFIC OFFICER

EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”) is pleased to announce that it has strengthened its organisational capability with the appointment of global medical imaging expert and innovator, Professor Stuart Crozier, in the role of Chief Scientific Officer for EMVision.

Professor Crozier is globally recognised for his breakthroughs in Magnetic Resonance Imaging (MRI). Prof Crozier co-invented signal correction technology that corrected magnetic field distortions to produce faster, clearer and more accurate images, without adding to the cost of the MRI machines. This technology was subsequently licensed to Siemens and GE Healthcare, and both companies incorporated Prof Crozier’s image-correction technology into all their MRI machines, representing around two-thirds of all MRI machines on the market, benefiting an estimated eight billion people. Professor Crozier is an Australian Academy of Technology and Engineering (ATSE) Fellow and received the prestigious Clunies-Ross award for his contributions to the field of MRI.

As Chief Scientific Officer, Prof Crozier will provide strategic direction, oversight and execution of the research and development efforts that underpin EMVision’s novel imaging products. Prof Crozier is a co-inventor of the EMVision imaging technology and is Chair of EMVision’s Clinical Advisory Board. Prof Crozier was previously the Director of Biomedical Engineering at the University of Queensland and will maintain a close relationship with the University.

Prof Stuart Crozier said, “It has been quite some time since a new medical imaging modality that has the potential of EMVision’s technology has appeared on the market and I am excited to be a part its clinical inception. I look forward to joining the talented team at EMVision and to work closely with academic colleagues and our clinical partners to bring the product(s) to market.”

EMVision CEO Dr Ron Weinberger said, “Stuart brings a wealth of experience in the imaging sector and has been a principal driver and co-inventor of the technology EMVision has obtained from UQ. He has shepherded the technology partnership with EMVision and his decision to join EMVision is a strong endorsement of the progress we have made and the immense opportunity ahead. I am excited to have Stuart join us in a critical role to help take us along the journey to a commercial product that will save lives.”

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.